Related Experiment Video
Updated: Aug 9, 2026
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
N Koch-Henriksen1, P S Sørensen, T Christensen
1Danish Multiple Sclerosis Registry, Rigshospitalet, Copenhagen, Denmark. koch-henriksen@stofanet.dk
Objective:
To investigate whether the efficacy of interferon-beta (IFNbeta) treatment of relapsing-remitting MS (RR-MS) was influenced by type, dose, and frequency of administration.
Methods:
From June 1996 through October 1997, the authors offered participation to all Danish RR-MS patients who met the following criteria: definite MS, at least two relapses within 2 years, age 18 to 55, and an Expanded Disability Status Scale (EDSS) score of < or = 5.5. The study was multicenter, controlled, open-label, randomized, head-to-head comparing IFNbeta-1a 22 microg once a week (n = 143) with IFNbeta-1b 250 microg every other day (n = 158), both subcutaneously, for 24 months. Patients who declined randomization were offered treatment with IFNbeta-1b 250 microg every other day (n = 120). The primary end-points were the annualized relapse rate, the time to first relapse, and neutralizing antibody formation. The secondary endpoint was time to sustained progression.
Results:
The annual relapse rates were virtually equal in the two arms of the randomized study (IFNbeta-1a: 0.70; IFNbeta-1b: 0.71); so were the time to first relapse and the time to sustained progression. In the nonrandomized patients (IFNbeta-1b), the annual relapse rate was not significantly different, but the time to progression was shorter.
Conclusion:
In this study, 250 microg interferon-beta-1b administered every other day did not prove clinically superior to once-a-week administration of 22 microg interferon-beta-1a.
Insights
Interferon-beta-1b administered every other day showed no clinical superiority over weekly interferon-beta-1a in treating relapsing-remitting MS. Both treatments demonstrated similar efficacy in reducing relapse rates and disease progression.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Relapsing-remitting multiple sclerosis (RR-MS) is a chronic autoimmune disease affecting the central nervous system.
- Interferon-beta (IFNbeta) is a common treatment for RR-MS, with various formulations and administration schedules available.
- Optimizing IFNbeta treatment efficacy requires understanding the impact of different administration types, doses, and frequencies.
Purpose of the Study:
- To compare the clinical efficacy of two different interferon-beta formulations in patients with RR-MS.
- To determine if the dose and frequency of interferon-beta administration influence treatment outcomes in RR-MS.
- To evaluate the impact of different interferon-beta treatments on relapse rates, time to relapse, and disease progression.
Main Methods:
- A multicenter, controlled, open-label, randomized head-to-head study comparing subcutaneous IFNbeta-1a (22 mcg weekly) with IFNbeta-1b (250 mcg every other day) for 24 months.
- Inclusion criteria: definite MS, at least two relapses in 2 years, age 18-55, EDSS score ≤5.5.
- A non-randomized group received IFNbeta-1b (250 mcg every other day). Primary endpoints: annualized relapse rate, time to first relapse, neutralizing antibody formation. Secondary endpoint: time to sustained progression.
Main Results:
- Annualized relapse rates were similar between randomized groups (IFNbeta-1a: 0.70; IFNbeta-1b: 0.71).
- Time to first relapse and time to sustained progression were comparable in the randomized arms.
- In the non-randomized IFNbeta-1b group, the annualized relapse rate was not significantly different, but the time to progression was shorter.
Conclusions:
- The study found no significant clinical superiority of 250 mcg of interferon-beta-1b administered every other day compared to 22 mcg of interferon-beta-1a administered weekly for RR-MS.
- Treatment efficacy in RR-MS may be influenced by factors beyond type, dose, and frequency, warranting further investigation.
- Both evaluated interferon-beta treatments demonstrated comparable outcomes in managing relapsing-remitting multiple sclerosis in this cohort.
More Related Videos
08:22Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
Published on: October 7, 2017
08:33A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
